Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR therapeutic protein, for relapsed or refractory NHL patients

John M. Pagel, Stephen E. Spurgeon, John C. Byrd, Farrukh T. Awan, Ian W. Flinn, Mark C. Lanasa, Amy J. Eisenfeld, Scott C. Stromatt, Ajay K. Gopal

Research output: Contribution to journalArticle

23 Scopus citations

Fingerprint Dive into the research topics of 'Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR<sup>™</sup> therapeutic protein, for relapsed or refractory NHL patients'. Together they form a unique fingerprint.

Medicine & Life Sciences